LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 60

Search options

  1. Article ; Online: Mycobacterium bovis infection mimicking pancreatic cancer.

    Yates, Joseph R / Lillie, Patrick J / Helbren, Emma / Samson, Annette D

    The Lancet. Infectious diseases

    2020  Volume 20, Issue 9, Page(s) 1099

    MeSH term(s) Aged, 80 and over ; Antitubercular Agents/therapeutic use ; Diagnosis, Differential ; Female ; Humans ; Mycobacterium bovis ; Pancreatic Neoplasms/diagnosis ; Tuberculosis/diagnosis ; Tuberculosis/microbiology ; Tuberculosis/pathology
    Chemical Substances Antitubercular Agents
    Language English
    Publishing date 2020-08-28
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 2061641-7
    ISSN 1474-4457 ; 1473-3099
    ISSN (online) 1474-4457
    ISSN 1473-3099
    DOI 10.1016/S1473-3099(19)30560-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Significantly lower 30 day/inpatient mortality observed in people who inject drugs (PWID) compared to non-PWID with Staphylococcus aureus bacteraemia.

    Mortimer, Isabel / Drury, Katie / Lowe, Shakeel / Akhtar, Marium / Barlow, Gavin D / Easom, Nicholas / Lillie, Patrick J

    The Journal of infection

    2022  Volume 85, Issue 4, Page(s) 436–480

    MeSH term(s) Bacteremia/complications ; Drug Users ; Humans ; Inpatients ; Staphylococcal Infections ; Staphylococcus aureus ; Substance Abuse, Intravenous/complications
    Language English
    Publishing date 2022-06-18
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 424417-5
    ISSN 1532-2742 ; 0163-4453
    ISSN (online) 1532-2742
    ISSN 0163-4453
    DOI 10.1016/j.jinf.2022.06.010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Systemic Inflammation Is Associated With Future Risk of Fatal Infection: An Observational Cohort Study.

    Drozd, Michael / Pujades-Rodriguez, Mar / Morgan, Ann W / Lillie, Patrick J / Witte, Klaus K / Kearney, Mark T / Cubbon, Richard M

    The Journal of infectious diseases

    2022  Volume 226, Issue 3, Page(s) 554–562

    Abstract: Background: Many diseases are associated with chronic inflammation, resulting in widening application of anti-inflammatory therapies. Although they are effective as disease-modifying agents, these anti-inflammatory therapies increase the risk of serious ...

    Abstract Background: Many diseases are associated with chronic inflammation, resulting in widening application of anti-inflammatory therapies. Although they are effective as disease-modifying agents, these anti-inflammatory therapies increase the risk of serious infection; however, it remains unknown whether chronic systemic inflammation per se is also associated with fatal infection.
    Methods: Using serum C-reactive protein (CRP) data from 461 052 UK Biobank participants, we defined incidence rate ratios (IRRs) for death from infection, cardiovascular disease, or other causes and adjusted for comorbidities and the use of anti-inflammatory therapies.
    Results: Systemic inflammation, defined as CRP ≥2 mg/L, was common in all comorbidities considered. After adjusting for confounding factors, systemic inflammation was associated with a higher IRR point estimate for infection death (1.70; 95% confidence interval [CI], 1.51-1.92) than cardiovascular (1.48; CI, 1.40-1.57) or other death (1.41; CI, 1.37-1.45), although CIs overlapped. C-reactive protein thresholds of ≥5 and ≥10 mg/L yielded similar findings, as did analyses in people with ≥2, but not <2, comorbidities.
    Conclusions: Systemic inflammation per se identifies people at increased risk of infection death, potentially contributing to the observed risks of anti-inflammatory therapies in clinical trials. In future clinical trials of anti-inflammatory therapies, researchers should carefully consider risks and benefits in target populations, guided by research into mechanisms of infection risk.
    MeSH term(s) Anti-Inflammatory Agents ; C-Reactive Protein ; Cardiovascular Diseases ; Cohort Studies ; Humans ; Inflammation
    Chemical Substances Anti-Inflammatory Agents ; C-Reactive Protein (9007-41-4)
    Language English
    Publishing date 2022-06-21
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 3019-3
    ISSN 1537-6613 ; 0022-1899
    ISSN (online) 1537-6613
    ISSN 0022-1899
    DOI 10.1093/infdis/jiac186
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: One-Year Outcomes of Critical Care Patients Post-COVID-19 Multisystem Inflammatory Syndrome in Children.

    Davies, Patrick / du Pré, Pascale / Lillie, Jon / Kanthimathinathan, Hari Krishnan

    JAMA pediatrics

    2021  Volume 175, Issue 12, Page(s) 1281–1283

    MeSH term(s) C-Reactive Protein/metabolism ; COVID-19/complications ; COVID-19/diagnosis ; COVID-19/therapy ; Child ; Child, Preschool ; Critical Care ; Female ; Hospitalization ; Humans ; Pandemics ; Respiratory Distress Syndrome/etiology ; Respiratory Distress Syndrome/therapy ; SARS-CoV-2 ; Systemic Inflammatory Response Syndrome
    Chemical Substances C-Reactive Protein (9007-41-4)
    Language English
    Publishing date 2021-08-30
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2701223-2
    ISSN 2168-6211 ; 2168-6203
    ISSN (online) 2168-6211
    ISSN 2168-6203
    DOI 10.1001/jamapediatrics.2021.2993
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: First Dose of BNT162b2 mRNA Vaccine in a Healthcare Worker Cohort Is Associated With Reduced Symptomatic and Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.

    Lillie, Patrick J / O'Brien, Paul / Lawtie, Michelle / Jessop, Steve / Easom, Nicholas J W / Patmore, Russell

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

    2021  Volume 73, Issue 10, Page(s) 1906–1908

    Abstract: Over the first 2 months of 2021, vaccination coverage of staff at Hull Teaching Hospitals with BNT162b2 increased from 8.3% to 82.5% and was associated with a significant reduction in symptomatic and asymptomatic severe acute respiratory syndrome ... ...

    Abstract Over the first 2 months of 2021, vaccination coverage of staff at Hull Teaching Hospitals with BNT162b2 increased from 8.3% to 82.5% and was associated with a significant reduction in symptomatic and asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cases. The proportion of positive lateral flow tests from asymptomatic screening was maintained over this period.
    MeSH term(s) BNT162 Vaccine ; COVID-19 ; COVID-19 Vaccines ; Health Personnel ; Humans ; RNA, Messenger ; SARS-CoV-2 ; Vaccines
    Chemical Substances COVID-19 Vaccines ; RNA, Messenger ; Vaccines ; BNT162 Vaccine (N38TVC63NU)
    Language English
    Publishing date 2021-04-13
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1099781-7
    ISSN 1537-6591 ; 1058-4838
    ISSN (online) 1537-6591
    ISSN 1058-4838
    DOI 10.1093/cid/ciab351
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Coevolution of Resistance to PPO Inhibitors in Waterhemp (Amaranthus tuberculatus) and Palmer Amaranth (Amaranthus palmeri)

    Lillie, Kathryn J / Giacomini, Darci A / Green, Jonathan D / Tranel, Patrick J

    Weed science. 2019 Oct. 22, v. 67, no. 5

    2019  

    Abstract: The first case of evolved protoporphyrinogen oxidase (PPO)-inhibitor resistance was observed in 2001 in common waterhemp [Amaranthus tuberculatus (Moq.) Sauer var. rudis (Sauer) Costea and Tardif]. This resistance in A. tuberculatus is most commonly ... ...

    Abstract The first case of evolved protoporphyrinogen oxidase (PPO)-inhibitor resistance was observed in 2001 in common waterhemp [Amaranthus tuberculatus (Moq.) Sauer var. rudis (Sauer) Costea and Tardif]. This resistance in A. tuberculatus is most commonly conferred by deletion of the amino acid glycine at the 210th position (ΔGly-210) of the PPO enzyme (PPO2) encoded by PPX2. In a field in Kentucky in 2015, inadequate control of Amaranthus plants was observed following application of a PPO inhibitor. Morphological observations indicated that survivors included both A. tuberculatus and Palmer amaranth (Amaranthus palmeri S. Watson). Research was conducted to confirm species identities and resistance and then to determine whether resistance evolved independently in the two species or via hybridization. Results from a quantitative PCR assay based on the ribosomal internal transcribed spacer confirmed that both A. tuberculatus and A. palmeri coexisted in the field. The mutation conferring ΔGly-210 in PPO2 was identified in both species; phylogenetic analysis of a region of PPX2, however, indicated that the mutation evolved independently in the two species. Genotyping of greenhouse-grown plants that survived lactofen indicated that all A. tuberculatus survivors, but only a third of A. palmeri survivors, contained the ΔGly-210 mutation. Consequently, A. palmeri plants were evaluated for the presence of an arginine to glycine or methionine substitution at position 128 of PPO2 (Arg-128-Gly and Arg-128-Met). The Arg-128-Gly substitution was found to account for resistance that was not accounted for by the ΔGly-210 mutation in plants from the A. palmeri population. Results from this study provide a modern-day example of both parallel and convergent evolution occurring within a single field.
    Keywords Amaranthus palmeri ; Amaranthus tuberculatus ; arginine ; coevolution ; convergent evolution ; genotyping ; glycine (amino acid) ; hybridization ; internal transcribed spacers ; lactofen ; methionine ; mutation ; phylogeny ; protoporphyrinogen oxidase ; quantitative polymerase chain reaction ; weed science ; Kentucky
    Language English
    Dates of publication 2019-1022
    Size p. 521-526.
    Publishing place The Weed Science Society of America
    Document type Article
    ZDB-ID 281279-4
    ISSN 0043-1745
    ISSN 0043-1745
    DOI 10.1017/wsc.2019.41
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  7. Article ; Online: Causes of Death in People With Cardiovascular Disease: A UK Biobank Cohort Study.

    Drozd, Michael / Pujades-Rodriguez, Mar / Sun, Fei / Franks, Kevin N / Lillie, Patrick J / Witte, Klaus K / Kearney, Mark T / Cubbon, Richard M

    Journal of the American Heart Association

    2021  Volume 10, Issue 22, Page(s) e023188

    Abstract: Background Therapeutic advances have reduced cardiovascular death rates in people with cardiovascular diseases (CVD). We aimed to define the rates of cardiovascular and noncardiovascular death in people with specified CVDs or accruing cardiovascular ... ...

    Abstract Background Therapeutic advances have reduced cardiovascular death rates in people with cardiovascular diseases (CVD). We aimed to define the rates of cardiovascular and noncardiovascular death in people with specified CVDs or accruing cardiovascular multimorbidity. Methods and Results We studied 493 280 UK residents enrolled in the UK Biobank cohort study. The proportion of deaths attributed to cardiovascular, cancer, infection, or other causes were calculated in groups defined by 9 distinct self-reported CVDs at baseline, or by the number of these CVDs at baseline. Poisson regression analyses were then used to define adjusted incidence rate ratios for these causes of death, accounting for sociodemographic factors and comorbidity. Of 27 729 deaths, 20.4% were primarily attributed to CVD, 53.6% to cancer, 5.0% to infection, and 21.0% to other causes. As cardiovascular multimorbidity increased, the proportion of cardiovascular and infection-related deaths was greater, contrasting with cancer and other deaths. Compared with people without CVD, those with 3 or more CVDs experienced adjusted incidence rate ratios of 7.0 (6.2-7.8) for cardiovascular death, 4.4 (3.4-5.6) for infection death, 1.5 (1.4-1.7) for cancer death, and 2.0 (1.7-2.4) for other causes of death. There was substantial heterogeneity in causes of death, both in terms of crude proportions and adjusted incidence rate ratios, among the 9 studied baseline CVDs. Conclusions Noncardiovascular death is common in people with CVD, although its contribution varies widely between people with different CVDs. Holistic and personalized care are likely to be important tools for continuing to improve outcomes in people with CVD.
    MeSH term(s) Biological Specimen Banks ; Cardiovascular Diseases/epidemiology ; Cardiovascular Diseases/mortality ; Cause of Death ; Cohort Studies ; Humans ; Risk Factors ; United Kingdom/epidemiology
    Language English
    Publishing date 2021-11-06
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2653953-6
    ISSN 2047-9980 ; 2047-9980
    ISSN (online) 2047-9980
    ISSN 2047-9980
    DOI 10.1161/JAHA.121.023188
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Non-communicable disease, sociodemographic factors, and risk of death from infection: a UK Biobank observational cohort study.

    Drozd, Michael / Pujades-Rodriguez, Mar / Lillie, Patrick J / Straw, Sam / Morgan, Ann W / Kearney, Mark T / Witte, Klaus K / Cubbon, Richard M

    The Lancet. Infectious diseases

    2021  Volume 21, Issue 8, Page(s) 1184–1191

    Abstract: Background: Non-communicable diseases (NCDs) have been highlighted as important risk factors for COVID-19 mortality. However, insufficient data exist on the wider context of infectious diseases in people with NCDs. We aimed to investigate the ... ...

    Abstract Background: Non-communicable diseases (NCDs) have been highlighted as important risk factors for COVID-19 mortality. However, insufficient data exist on the wider context of infectious diseases in people with NCDs. We aimed to investigate the association between NCDs and the risk of death from any infection before the COVID-19 pandemic (up to Dec 31, 2019).
    Methods: For this observational study, we used data from the UK Biobank observational cohort study to explore factors associated with infection death. We excluded participants if data were missing for comorbidities, body-mass index, smoking status, ethnicity, and socioeconomic deprivation, and if they were lost to follow-up or withdrew consent. Deaths were censored up to Dec 31, 2019. We used Poisson regression models including NCDs present at recruitment to the UK Biobank (obesity [defined by use of body-mass index] and self-reported hypertension, chronic heart disease, chronic respiratory disease, diabetes, cancer, chronic liver disease, chronic kidney disease, previous stroke or transient ischaemic attack, other neurological disease, psychiatric disorder, and chronic inflammatory and autoimmune rheumatological disease), age, sex, ethnicity, smoking status, and socioeconomic deprivation. Separate models were constructed with individual NCDs replaced by the total number of prevalent NCDs to define associations with multimorbidity. All analyses were repeated with non-infection-related death as an alternate outcome measure to establish differential associations of infection death and non-infection death. Associations are reported as incidence rate ratios (IRR) accompanied by 95% CIs.
    Findings: After exclusion of 9210 (1·8%) of the 502 505 participants in the UK Biobank cohort, our study sample comprised 493 295 individuals. During 5 273 731 person-years of follow-up (median 10·9 years [IQR 10·1-11·6] per participant), 27 729 deaths occurred, of which 1385 (5%) were related to infection. Advancing age, male sex, smoking, socioeconomic deprivation, and all studied NCDs were independently associated with the rate of both infection death and non-infection death. Compared with White ethnicity, a pooled Black, Asian, and minority ethnicity group was associated with a reduced risk of infection death (IRR 0·64, 95% CI 0·46-0·87) and non-infection death (0·80, 0·75-0·86). Stronger associations with infection death than with non-infection death were observed for advancing age (age 65 years vs 45 years: 7·59, 95% CI 5·92-9·73, for infection death vs 5·21, 4·97-5·48, for non-infection death), current smoking (vs never smoking: 3·69, 3·19-4·26, vs 2·52, 2·44-2·61), socioeconomic deprivation (most vs least deprived quintile: 2·13, 1·78-2·56, vs 1·38, 1·33-1·43), class 3 obesity (vs non-obese: 2·21, 1·74-2·82, vs 1·55, 1·44-1·66), hypertension (1·36, 1·22-1·53, vs 1·15, 1·12-1·18), respiratory disease (2·21, 1·96-2·50, vs 1·28, 1·24-1·32), chronic kidney disease (5·04, 4·28-7·31, vs 2·50, 2·20-2·84), psychiatric disease (1·56, 1·30-1·86, vs 1·23, 1·18-1·29), and chronic inflammatory and autoimmune rheumatological disease (2·45, 1·99-3·02, vs 1·41, 1·32-1·51). Accrual of multimorbidity was also more strongly associated with risk of infection death (five or more comorbidities vs none: 9·53, 6·97-13·03) than of non-infection death (5·26, 4·84-5·72).
    Interpretation: Several NCDs are associated with an increased risk of infection death, suggesting that some of the reported associations with COVID-19 mortality might be non-specific. Only a subset of NCDs, together with the accrual of multimorbidity, advancing age, smoking, and socioeconomic deprivation, were associated with a greater IRR for infection death than for other causes of death. Further research is needed to define why these risk factors are more strongly associated with infection death, so that more effective preventive strategies can be targeted to high-risk groups.
    Funding: British Heart Foundation.
    MeSH term(s) Adult ; Aged ; Biological Specimen Banks ; COVID-19/etiology ; COVID-19/mortality ; Female ; Humans ; Male ; Middle Aged ; Noncommunicable Diseases ; Risk Factors ; SARS-CoV-2 ; Socioeconomic Factors
    Language English
    Publishing date 2021-03-01
    Publishing country United States
    Document type Journal Article ; Observational Study ; Research Support, Non-U.S. Gov't
    ZDB-ID 2061641-7
    ISSN 1474-4457 ; 1473-3099
    ISSN (online) 1474-4457
    ISSN 1473-3099
    DOI 10.1016/S1473-3099(20)30978-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Differential Vulnerability and Response to Injury Among Brain Cell Types Comprising the Neurovascular Unit.

    Rajput, Padmesh / Brookshier, Allison / Kothari, Shweta / Eckstein, Lillie / Chang, Heather / Liska, Sophie / Lamb, Jessica / Sances, Samuel / Lyden, Patrick

    The Journal of neuroscience : the official journal of the Society for Neuroscience

    2024  

    Abstract: The neurovascular unit includes multiple different cell types, including neurons, astrocytes, endothelial cells and pericytes, which respond to insults on very different time or dose scales. We defined differential vulnerability among these cell types, ... ...

    Abstract The neurovascular unit includes multiple different cell types, including neurons, astrocytes, endothelial cells and pericytes, which respond to insults on very different time or dose scales. We defined differential vulnerability among these cell types, using response to two different insults: oxygen-glucose deprivation and thrombin-mediated cytotoxicity. We found that neurons are most vulnerable, followed by endothelial cells, followed by astrocytes. After temporary focal cerebral ischemia in male rats, we found significantly more injured neurons, compared to astrocytes in the ischemic area, consistent with differential vulnerability in vivo. We sought to illustrate different and shared mechanisms across all cell types during response to insult. We found that gene expression profiles in response to oxygen-glucose deprivation differed among the cell types, with a paucity of gene responses shared by all types. All cell types activated genes relating to autophagy, apoptosis, and necroptosis, but the specific genes differed. Astrocytes and endothelial cells also activated pathways connected to DNA repair and anti-apoptosis. Taken together, the data support the concept of differential vulnerability in the neurovascular unit and suggests that different elements of the unit will evolve from salvageable to irretrievable on different time scales while residing in the same brain region and receiving the same (ischemic) blood flow. Future work will focus on the mechanisms of these differences. These data suggest future stroke therapy development should target different elements of the NVU differently.
    Language English
    Publishing date 2024-03-28
    Publishing country United States
    Document type Journal Article
    ZDB-ID 604637-x
    ISSN 1529-2401 ; 0270-6474
    ISSN (online) 1529-2401
    ISSN 0270-6474
    DOI 10.1523/JNEUROSCI.1093-22.2024
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Tedizolid: a service evaluation in a large UK teaching hospital.

    York, Joshua A / Adams, Kate / Cullen, Lorraine / Delahay, Joanne / Ivan, Monica / Lillie, Patrick J / MacLachlan, Laura / Barlow, Gavin

    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology

    2020  Volume 40, Issue 2, Page(s) 397–405

    Abstract: Tedizolid is a new oxazolidinone antibiotic with little real-life data on use outside of skin and soft tissue infections. There is a paucity of safety evidence in courses greater than 6 days. Our centre uses tedizolid predominantly when linezolid- ... ...

    Abstract Tedizolid is a new oxazolidinone antibiotic with little real-life data on use outside of skin and soft tissue infections. There is a paucity of safety evidence in courses greater than 6 days. Our centre uses tedizolid predominantly when linezolid-associated adverse events have occurred. This service evaluation describes our experience to date. We performed a retrospective service evaluation by reviewing case notes, prescription charts, and laboratory system results for each patient prescribed tedizolid at our hospital and recording patient demographics, clinical details, and outcomes. Sixty patients received tedizolid between May 2016 and November 2018. Most were treated for bone or joint infections and had stopped linezolid prior to tedizolid prescription. Mean length of tedizolid therapy was 27 days. Haematological adverse effects were infrequent. Most patients (72%) finished the course and their clinical condition improved during treatment (72%). Adverse events were common, but often not thought to be tedizolid related. Tedizolid appears to be safe in prolonged courses within this context. It may be suitable for longer-term antibiotic therapy within a complex oral and parenteral outpatient antibiotic therapy (COPAT) service. Patients who do not tolerate linezolid can be safely switched to tedizolid if appropriate.
    MeSH term(s) Anti-Bacterial Agents/adverse effects ; Anti-Bacterial Agents/therapeutic use ; Bone Diseases, Infectious/drug therapy ; Female ; Hospitals, Teaching ; Humans ; Linezolid/therapeutic use ; Male ; Middle Aged ; Oxazolidinones/adverse effects ; Oxazolidinones/therapeutic use ; Retrospective Studies ; Tetrazoles/adverse effects ; Tetrazoles/therapeutic use ; Treatment Outcome ; United Kingdom
    Chemical Substances Anti-Bacterial Agents ; Oxazolidinones ; Tetrazoles ; tedizolid (97HLQ82NGL) ; Linezolid (ISQ9I6J12J)
    Language English
    Publishing date 2020-08-26
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 603155-9
    ISSN 1435-4373 ; 0934-9723 ; 0722-2211
    ISSN (online) 1435-4373
    ISSN 0934-9723 ; 0722-2211
    DOI 10.1007/s10096-020-04015-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top